Opportunity Information: Apply for PA 15 077
Apply for PA 15 077
- The National Institutes of Health in the food and nutrition health income security and social services sector is offering a public funding opportunity titled "New Technologies for Viral Hepatitis SBIR (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839 Blood Diseases and Resources Research 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Dec 18, 2014 and posted on Dec 18, 2014.
- Applicants must submit their applications by Jan 7, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria 1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor 2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture 3. i. SBIR and STTR. Be a concern which is more than 50 directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50 directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these OR ii. SBIR only. Be a concern which is more than 50 owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50 of the concern OR iii. SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with 121.705(b) concerning registration and proposal requirements. 4. Has, including its affiliates, not more than 500 employees.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The New Technologies for Viral Hepatitis SBIR (R43/R44) opportunity (Funding Opportunity Number PA 15-077) is an NIH discretionary grant program designed to push small businesses to develop and commercialize new technologies that improve how viral hepatitis is prevented, detected, monitored, and treated. The core intent is to stimulate innovation that directly supports priorities laid out in the U.S. Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis, while also fitting within the research missions of the participating NIH institutes. In practical terms, the program is aimed at moving technology-focused ideas from early feasibility work into more advanced development with a clear path toward real-world use.
This announcement uses the Small Business Innovation Research (SBIR) mechanism and supports both Phase I and Phase II projects under the R43/R44 activity codes. Phase I (R43) is generally used to establish scientific and technical merit and show early feasibility, while Phase II (R44) typically supports more extensive research and development efforts that build on Phase I results. Because it is an SBIR opportunity, the emphasis is not just on producing academic knowledge, but on creating tangible products, platforms, or tools that can reach the market or be adopted by health systems and public health programs.
Eligibility is limited to U.S. small business concerns (SBCs). To qualify, an applicant must be a for-profit organization with a place of business in the United States and must operate primarily in the U.S. or contribute significantly to the U.S. economy through taxes or the use of American products, materials, or labor. Acceptable legal structures include sole proprietorships, partnerships, LLCs, corporations, joint ventures, associations, trusts, and cooperatives, with specific limits on foreign participation in joint ventures (less than 50 percent). Ownership and control requirements follow SBIR rules, allowing majority ownership by U.S. citizens or permanent residents, or in certain SBIR-only cases, majority ownership by multiple venture capital operating companies, hedge funds, or private equity firms so long as no single such entity owns more than 50 percent. The small business (including affiliates) must also have no more than 500 employees at the time of award. There is no cost sharing or matching requirement, which means applicants are not required to provide additional non-federal funds to receive an award.
The program is administered by the National Institutes of Health and is associated with multiple CFDA numbers, reflecting involvement across NIH mission areas: 93.839 (Blood Diseases and Resources Research), 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), and 93.865 (Child Health and Human Development Extramural Research). This mix signals that the scope can include technology development relevant to hepatitis across different populations and clinical contexts, including liver and digestive health, blood-borne transmission considerations, and maternal/child health dimensions.
Key administrative details in the source information include a posted and created date of December 18, 2014, with an original and current closing date of January 7, 2018, and an archive date of February 7, 2018. The funding instrument type is listed as a grant, and the opportunity category is discretionary. For official details and full requirements, applicants were directed to the NIH funding announcement page (http://grants.nih.gov/grants/guide/pa-files/PA-15-077.html). For access or technical issues, the listed contact was the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs)
What is the New Technologies for Viral Hepatitis SBIR (R43/R44) opportunity?
It is an NIH discretionary grant program (Funding Opportunity Number PA 15-077) that supports U.S. small businesses developing and commercializing new technologies to improve how viral hepatitis is prevented, detected, monitored, and treated.
What is the main purpose of this funding opportunity?
The core intent is to stimulate small business innovation that aligns with the U.S. Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis and fits within the research missions of participating NIH institutes. The program is intended to move technology-focused ideas from early feasibility work into more advanced development with a clear path to real-world use.
What kinds of projects are encouraged under this announcement?
Projects focused on developing and commercializing tangible technologies that improve prevention, detection, monitoring, or treatment of viral hepatitis. The emphasis is on product- or tool-oriented development (such as technologies, platforms, or tools) that can reach the market or be adopted by health systems and public health programs.
What funding mechanism does this opportunity use?
This announcement uses the Small Business Innovation Research (SBIR) mechanism and supports Phase I and Phase II projects under the NIH R43/R44 activity codes.
What is the difference between Phase I (R43) and Phase II (R44) for this opportunity?
Phase I (R43) is generally used to establish scientific and technical merit and demonstrate early feasibility. Phase II (R44) typically supports more extensive research and development that builds on Phase I results.
Is the focus primarily academic research or product development?
The focus is not just on producing academic knowledge. Because it is an SBIR program, the emphasis is on developing tangible products, platforms, or tools with a clear path toward commercialization or adoption in real-world settings.
Who is eligible to apply?
Eligibility is limited to U.S. small business concerns (SBCs) that meet SBIR eligibility requirements.
What basic organizational requirements must an applicant meet to qualify as an eligible small business?
The applicant must be a for-profit organization with a place of business in the United States and must operate primarily in the U.S. or contribute significantly to the U.S. economy through taxes or the use of American products, materials, or labor.
What legal entity types are allowed to apply?
Acceptable legal structures include sole proprietorships, partnerships, LLCs, corporations, joint ventures, associations, trusts, and cooperatives.
Are joint ventures allowed, and are there limits on foreign participation?
Joint ventures are an acceptable legal structure. The provided information notes specific limits on foreign participation in joint ventures (less than 50 percent).
What are the ownership and control requirements under SBIR for this opportunity?
Ownership and control requirements follow SBIR rules. In general, majority ownership by U.S. citizens or permanent residents is allowed. In certain SBIR-only cases, majority ownership by multiple venture capital operating companies, hedge funds, or private equity firms is allowed, as long as no single such entity owns more than 50 percent.
Is there a size limit for the small business?
Yes. The small business concern (including affiliates) must have no more than 500 employees at the time of award.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement, meaning applicants are not required to provide additional non-federal funds to receive an award.
Which federal agency administers this opportunity?
The program is administered by the National Institutes of Health (NIH).
Which CFDA numbers are associated with this opportunity?
The opportunity is associated with multiple CFDA numbers: 93.839 (Blood Diseases and Resources Research), 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), and 93.865 (Child Health and Human Development Extramural Research).
What does it mean that multiple CFDA numbers are listed?
Based on the provided information, the mix of CFDA numbers reflects involvement across NIH mission areas and signals that the scope can include hepatitis-related technology development across different populations and clinical contexts, including liver and digestive health, blood-borne transmission considerations, and maternal/child health dimensions.
What is the funding instrument type and opportunity category?
The funding instrument type is a grant, and the opportunity category is discretionary.
When was this opportunity posted, and what were the key dates?
The posted and created date is December 18, 2014. The original and current closing date is January 7, 2018. The archive date is February 7, 2018.
Where can applicants find the official funding announcement and full requirements?
Applicants were directed to the NIH funding announcement page at: http://grants.nih.gov/grants/guide/pa-files/PA-15-077.html
Who should be contacted for access or technical issues related to the announcement page?
For access or technical issues, the listed contact is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
What is the Funding Opportunity Number (FON) for this announcement?
The Funding Opportunity Number is PA 15-077.
Does this opportunity explicitly support commercialization-oriented work?
Yes. The provided description states that the program is designed to push small businesses to develop and commercialize new technologies, with an emphasis on tangible outputs that can reach the market or be adopted by health systems and public health programs.
What broad public health goals does the program aim to support?
It aims to support innovation that advances priorities in the U.S. Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis, specifically through technologies that improve prevention, detection, monitoring, and treatment.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health Income Security and Social Services
Next opportunity: Program Expansion Supplement for Advancing National Public Health Institutes Globally
Previous opportunity: New Technologies for Viral Hepatitis STTR (R41/R42)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 15 077
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 15 077) also looked into and applied for these:
| Funding Opportunity |
|---|
| Closed Loop Technologies Clinical and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (R01) Apply for RFA DK 08 012 Funding Number: RFA DK 08 012 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $500,000 |
| Closed Loop Technologies Pilot and Exploratory Clinical and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (R21) Apply for RFA DK 08 013 Funding Number: RFA DK 08 013 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $200,000 |
| Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D). Towards an Artificial Pancreas (SBIR) R43/R44) Apply for RFA DK 09 001 Funding Number: RFA DK 09 001 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Type 1 Diabetes TrialNet Clinical Centers (U01) Apply for RFA DK 08 011 Funding Number: RFA DK 08 011 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research for the Prevention and Control of Diabetes and Obesity (R18) Apply for PAR 09 176 Funding Number: PAR 09 176 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $500,000 |
| Planning Grants for Translational Research for the Prevention and Control of Diabetes and Obesity (R34) Apply for PAR 09 177 Funding Number: PAR 09 177 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $300,000 |
| Basic and Clinical Studies of Congenital Urinary Tract Obstruction (R01) Apply for PA 09 226 Funding Number: PA 09 226 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D). Towards an Artificial Pancreas (SBIR) (R43/R44) Apply for RFA DK 10 008 Funding Number: RFA DK 10 008 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R01) Apply for PAR 10 230 Funding Number: PAR 10 230 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R21) Apply for PAR 10 232 Funding Number: PAR 10 232 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $200,000 |
| A GenitoUrinary Development Molecular Anatomy Project (GUDMAP) Database and Website (U01) Apply for RFA DK 10 005 Funding Number: RFA DK 10 005 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Lifestyle Interventions in Overweight and Obese Pregnant Women Consortium (U01) Apply for RFA DK 10 014 Funding Number: RFA DK 10 014 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Feasibility Studies for Clinical Trials in Type 1 Diabetes (R03) Apply for RFA DK 11 007 Funding Number: RFA DK 11 007 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $50,000 |
| Clinical Trial Planning Grants in Type 1 Diabetes (R34) Apply for RFA DK 11 010 Funding Number: RFA DK 11 010 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 15 077", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.